Photo: News Nation
DGCI Approves Research On Mixing Two Covid Vaccines
The Drugs Controller General of India (DCGI) on August 10 gave permission for conducting a study on the mixing of doses of Covaxin and Covishield vaccines against the Covid-19 virus. It advised that the research and trials will be done by Christian College in Vellore. The Indian Council for Medical Research (ICMR) in its previous study disclosed that combining the two vaccines has shown "better immunogenicity."
Tags: Covid-19, COVISHIELD, Covaxin, DGCI, ICMR Research
Courtesy: The Times of India
Photo: The Times of India
Mixing Of Different Vaccines Produce Good Results: ICMR Research
ICMR has revealed that the mixing of two different vaccines based on the ''adenovirus vector'' does not produce any adverse effects. Furthermore, the research revealed that mixing helps to fight the COVID-19 virus and also produces immunity better than excepted. The research in India also helps to mitigate the rumors about the adverse effects of vaccines. Reportedly, many countries have proven this process to be promising.
Tags: ICMR, Coronavirus Vaccines, Mixed Dose, COVISHIELD, Covaxin
Courtesy: News Daily India
Photo: DNA
Bharat Biotech's Covaxin Receives GMP Certificate From Hungary
Good Manufacturing Practices (GMP) compliance certificate from Hungary has been granted to Bharat Biotech’s Covid-19 vaccine Covaxin. The company on August 6 took to Twitter saying, “This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulators.” The company stated that it aims to submit its documentation across the globe for emergency use authorization. Besides, it has been registered on the… read-more
Tags: Covaxin, Bharat biotech, Hungary, WHO-GMP
Courtesy: The Hindu
Photo: India.com
India's Covaxin Effective Against Delta+ Variant, Claims ICMR Study
According to the study done by the Indian Council of Medical Research (ICMR), India's Covaxin developed by Bharat Biotech is potent against the Delta Plus (AY.1) variant of the SARS-CoV2 virus. The Delta AY.1 variant was first detected in India in April 2021 but is found to be low. "Our research showed that Covaxin could still neutralize Delta, AY.1 and B.1.617.3 variants," said Dr. Samiran Panda, head of epidemiology and communicable… read-more
Tags: Covid-19, Covaxin, ICMR, Delta Variant
Courtesy: Indian Express
Photo: Bing
Brazil Government Shuts Import Of Bharat Biotech's Covaxin
The Brazilian government has scrapped the import and distribution of 4 million jabs of India's Bharat Biotech's Covaxin following the country's decision to dismiss the clinical trials and the request for Emergency Use Authorization. "The Collegiate Board of Anvisa unanimously decided on July 27 to provisionally suspend the exceptional and temporary authorization for import and distribution of the vaccine against Covid-19", said the National… read-more
Tags: Brazil, Covid-19, Covaxin, Brazil Deal
Courtesy: The Print
Photo: The Times of India
WHO Commences Review Process Of Covaxin For Emergency Use
Bharat Biotech has submitted all the required documents for Emergency Use Listing (EUL) of "Covaxin" vaccination on July 9th and WHO has began the process for approval, said Minister of State for Health Bharati Pravin Pawar on July 27. Further, she added that the WHO will take a duration of six weeks on the decision. Meanwhile, the Central Government is working relentlessly for the emergency approval of Covaxin.
Tags: WHO, Covaxin, Bharat biotech, Covid-19, Coronavirus Vaccines
Courtesy: News 18
Photo: The Hindu
Brazil Cancels Bharat Biotech's Covaxin Clinical Studies Due To Controversy
Following the controversy related to the deal with the Brazilian government for the supply of 20 million doses of vaccine led to the suspension of clinical studies of 'Bharat Bio-Tech Covaxin.’ It thus terminated Bharat Biotech’s agreement with its partner. The MoU signed with Precisa Medicamentos and Envixia Pharmaceuticals LLC for its Covid-19 vaccine Covaxin for the Brazilian… read-more
Tags: Bharat biotech, Brazil, Covid-19, Covaxin
Courtesy: PTI
Photo:The Mirror
Government Procures Covishield For Rs 215; Covaxin At Rs 225
In wake of the COVID-19 crisis, the Centre has ordered 66 crores doses of newly manufactured vaccines. The vaccines will be available at a revised price of Rs 215 & Rs 225 for Covishield and Covaxin respectively. However, a senior official said, “We are on the path to achieving the target of 50 crore doses by July 31, this is crucial towards meeting our target coverage by 2021.”
Tags: Covaxin, COVISHIELD, Government of India, Covid-19
Courtesy: The Times of India
Covaxin
India's Homegrown Covaxin To Get WHO Approval Soon
WHO is likely to take a call on emergency use listing of India's homegrown 'Covaxin' developed by Bharat Biotech in four to six weeks, Chief WHO Scientist Dr. Soumy Swaminathan said. The safety data, complete trial data, and manufacturing quality data for approval have been submitted by Bharat Biotech for review. Covaxin is now accepted in 16 countries and has shown 77.8% efficiency against symptomatic infection, as per reports.
Tags: Covid-19, Covaxin, Emergency Use Listing, WHO, WHO Chief
Courtesy: Hindustan Times
Photo: Financial Express
Covaxin's Phase-3 Trial Results Out, Claims To Be 77.8% Effective
Hyderabad-based Bharat Biotech has released the phase-3 clinical trial results of "Covaxin" on July 3, claiming it to be 77.8% successful. Moreover, the company said that it provides 63.6% protection to asymptomatic COVID-19 patients and is 65.2% effective against the SARS-CoV-2 & B.1.617.2 Delta variant. The vaccine is said to be 93.4% effective against severe symptomatic cases. As far as safety is concerned, Covaxin's effects are much… read-more
Tags: Covaxin, clinical trial, Bharat biotech, third phase, Delta Variant
Courtesy: The Siasat Daily
